循环微RNA及细胞外囊泡微RNA作为NSCLC抗PD-1/PD-L1治疗反应生物标志物
本研究分析晚期NSCLC患者抗PD-1/PD-L1治疗前血浆,用尺寸排阻色谱分离细胞外囊泡并进行miRNA测序。14例应答者与15例非应答者比较,全血浆32个miRNA及7个EV相关miRNA浓度差异显著,部分在独立队列验证,提示其作为预测生物标志物的潜力。
要点
- 全血浆32个miRNA在应答与非应答者间浓度差异显著(p=0.0030-0.0495)。
- 7个EV相关miRNA在两组间差异显著(p=0.041-0.0457)。
- 部分循环miRNA在独立队列(8例应答、13例非应答)中得到验证。
核心结论
- 全血浆和血浆EV中的特定循环miRNA在抗PD-1/PD-L1治疗应答者与非应答者间差异表达,有潜力作为预测治疗反应的生物标志物。
研究设计与样本
- 研究使用接受单药抗PD-1或抗PD-L1抗体治疗的晚期NSCLC患者治疗前血浆。
- 采用尺寸排阻色谱分离血浆EV,提取全血浆及含EV的RNA,用下一代测序平台分析miRNA谱。
- 分析14例应答者(部分缓解或疾病稳定≥6个月)和15例非应答者(按RECIST判定为疾病进展)的样本。
- 部分循环miRNA结果在独立队列(8例应答者、13例非应答者)中验证。
- 对两个队列中患者的肿瘤PD-L1水平采用免疫组化评估。
主要发现
- 全血浆中32个miRNA在应答者与非应答者间浓度差异显著(p=0.0030-0.0495)。
- 7个EV相关miRNA在应答者与非应答者间浓度差异显著(p=0.041-0.0457)。
- 部分循环miRNA的差异表达在独立队列中得到验证。
临床怎么用
- 治疗前血浆循环miRNA及EV相关miRNA或可作为抗PD-1/PD-L1治疗反应的预测生物标志物,辅助筛选获益人群。
局限性
- 部分miRNA结果仅在独立队列中验证,尚未明确临床可用的阈值或检测标准化方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Anti-programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) antibody therapy is a standard treatment for advanced NSCLC, and PD-L1 immunohistochemistry is used as a predictive biomarker for therapeutic response. However, because not all patients with NSCLC with high PD-L1 respond, and some patients with low PD-L1 expression exhibit durable benefit, more accurate predictive biomarkers are needed. Circulating microRNA (miRNA) and miRNA packaged in extracellular vesicles (EVs) are believed to play a role in intercellular communication among immune cells and between immune cells and tumor cells and may represent a good source of mechanism-related biomarkers. METHODS: Pretreatment plasma of patients with advanced NSCLC treated with single-agent anti-PD-1 or anti-PD-L1 antibody was used in this study. Plasma EVs were isolated using size-exclusion chromatography. Whole plasma and EV-containing RNAs were extracted. The miRNA profile was analyzed with a next-generation sequencing platform. RESULTS: Samples from 14 responders (patients who exhibited partial response or stable disease ≥6 mo) and 15 nonresponders (patients who exhibited progressive disease as per Response Evaluation Criteria in Solid Tumors) were analyzed. In total, 32 miRNAs (p = 0.0030-0.0495) from whole plasma and seven EV-associated miRNAs (p = 0.041-0.0457) exhibited significant concentration differences between responders and nonresponders. The results of some of these circulating miRNAs were validated in a separate cohort with eight responders and 13 nonresponders. The tumor PD-L1 level was also assessed using immunohistochemistry for patients involved in both cohorts. CONCLUSIONS: Specific circulating miRNAs in whole plasma and plasma EVs are differentially expressed between responders and nonresponders and have potential as predictive biomarkers for anti-PD-1/PD-L1 treatment response.
引用
- Shukuya T, Ghai V, Amann JM, et al. Circulating MicroRNAs and Extracellular Vesicle-Containing MicroRNAs as Response Biomarkers of Anti-programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC. J Thorac Oncol. 2020. PMID: 32565389. doi:10.1016/j.jtho.2020.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。